Headwinds persist for the Arthroscopic Technologies Market in Q322

With most of the major headwinds caused by COVID-19 in the rear-view mirror, the Arthroscopic Technologies (AT) Market showed growth in the third quarter with WW Arthroscopic Technologies revenues up +4.2% over Q321. The quarter saw a continued rise in procedural volumes globally that resulted in growth for the AT disposables market which trends with case volumes. On the capital side of the AT Market, capital spending and demand remained strong for items such as arthroscopic camera systems with new equipment purchases as well as an increasing need for replacement capital driving demand.

Among the many topics covered in detail in our comprehensive Q322 Arthroscopic Technologies Market Recap* are:

With the recent announcement that 3M is spinning off its Health Care division, SmartTRAK looks back at the evolution of 3M Health Care, its businesses today, the entry into Advanced Wound Care (AWC) and potential new opportunities for the new Health Care business.

3M, a large, diversified company with annual sales of $35.4B in 2021 announced earlier this year plans to spin-off its Health Care business into a new public company. Today, 3M markets thousands of products through four business groups: Safety and Industrial, Transportation and Electronics, Health Care and Consumer. Post-spin-off, 3M will continue as a leading global material science innovator, while the new stand-alone business will seek to become a global diversified healthcare company focused on wound care, healthcare IT, oral care and biopharma filtration.


Among the many topics covered in this fascinating article are:

SmartTRAK reports that Q322 Spine Market performance drove a lack of consensus on operational performance metrics, while a shifting procedural landscape offered new product opportunities for small and mid-tier players, driving competitive pressure.

Among the many topics covered in detail in our comprehensive Q322 Spine Market Recap* are:

Biosynthetic hernia matrices continue their ascent and Xenograft hernia matrices grow, thanks to TELA Bio.

As elective surgical procedures settle into pre-pandemic levels, the US Surgical Matrices Market resumed trends that had begun prior to Q322, gaining +2.4% YoY according to SmartTRAK Financial Dashboard. AbbVie* and Becton Dickinson* (BD) have been trading share positions in the last few quarters and now once again AbbVie has first place in the Q322 Surgical Matrices market despite of a -5.4% YoY decline, with BD In second place.

Among the many topics covered in detail in our comprehensive Q322 US Surgical Matrices Market Recap* are:

Despite declining OUS results, the US Trauma Market experienced healthy growth attributed to adoption of new products.

While OUS results declined in Q322 due to foreign currency headwinds and China’s value-based pricing, the US drove the overall market through product penetration and easier comps due to the Q321 COVID waves that impacted procedural volumes last year. Companies posted healthy US growth, attributing new products for driving growth, with plans for additional launches in Q4 and 2023.

Among the many topics covered in detail in our comprehensive Q322 Trauma Market Recap* are:

Growth in the SCS and DBS segments remained soft in Q322 as companies continue to wrestle with macro-environmental issues and currency headwinds

Neuromodulation continued to face a challenging macro environment in Q322 related to stubborn inflationary pressures, currency exchange headwinds and unpredictable surges in COVID affecting supply chains and healthcare staffing in certain geographies. However, some competitors reported seeing steady signs of improvement in the quarter and are looking to expanded indications and new technologies to help drive growth.

Among the many topics covered in detail in our comprehensive Q322 Neuromodulation Market Recap* are:

Surgeons are concerned about the cost of breast matrices in an increasingly restrictive environment, but alternatives may be on the horizon according to key discussions at the 2022 Plastic Surgery: The Meeting.

Breast matrices are used to cover breast implants in breast reconstruction and cosmetic breast surgeries. The matrices have become in effect standard of care in these surgeries, though they do not have FDA-approved indications for breast reconstruction or cosmetic breast surgeries. Moreover, the FDA has in recent years, issued warning letters and communications related to breast matrices. In 2015, the FDA issued warning letters reminding several companies that they did not ...

To read the complete "Trends in ADM Use from ASPS 2022" article by Doug Devens, SmartTRAK's Product Director/Sr. Analyst - Wound, in which  he shares observations from the ASPS sessions and the potential implications for the Breast Matrices Market, just click the following link.

Q322 sees a tidal wave of new robotic spine surgery competitors as well as data-driven initiatives under development by a host of companies in the market for spine enabling tech.

Q322 was nothing short of a tidal wave of competitive entrants to the US Spine Robotic Surgery space. Medtronic* (MDT) and  Globus* remain top players as OUS companies like France’s  eCential Robotics* and Taiwan’s  Point Robotics MedTech* set their sights on the US market. The Q322 WW CAS Spine Market was up, according to  SmartTRAK Financial Dashboard. MDT remained the market leader with 49.0% share, followed by Globus and other enabling tech competitors like Brainlab* and Stryker* (SYK).

Among the many topics covered in detail in our comprehensive Q322 CAS Spine Market Recap* are:

CMS Reimbursement changes raging like a beast to belabor several HA market players

For Q322, the true impact of CMS reimbursement changes was blatantly apparent, with the US Joint Fluid Replacement Market showing an overall lackluster revenue performance, with a YoY decline of -4.7% vs Q321, according to SmartTRAK Financial Dashboard. As if the new CMS regulations were not enough, the swing toward negative growth was also driven by hyaluronic (HA) companies battling for product placement, preferred formulary status with private payers, overall inflation, and still to a certain degree, supply chain-related issues stemming from COVID-19 and subsequent waves of the different variants. Aggregate revenue being in the red for the third quarter of 2022 was mainly the result of negative YoY growth across three of the four HA segments. Still, with an anticipated hard push to more positive year-end results, the US Joint Fluid Replacement Market is trending toward achieving on or ever so slightly above  SmartTRAK’s US Joint Fluid Replacement Market Overview revenue projections

Among the many topics covered in detail in our comprehensive Q322 US Joint Fluid Replacement Market Recap* are: